CA2478081A1 - Multiple and multivalent dna vaccines in ovo - Google Patents

Multiple and multivalent dna vaccines in ovo Download PDF

Info

Publication number
CA2478081A1
CA2478081A1 CA002478081A CA2478081A CA2478081A1 CA 2478081 A1 CA2478081 A1 CA 2478081A1 CA 002478081 A CA002478081 A CA 002478081A CA 2478081 A CA2478081 A CA 2478081A CA 2478081 A1 CA2478081 A1 CA 2478081A1
Authority
CA
Canada
Prior art keywords
virus
dna
avian
vaccine according
dna vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002478081A
Other languages
French (fr)
Other versions
CA2478081C (en
Inventor
Tsun-Yung Kuo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schweitzer Chemical Corp
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2478081A1 publication Critical patent/CA2478081A1/en
Application granted granted Critical
Publication of CA2478081C publication Critical patent/CA2478081C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16311—Mardivirus, e.g. Gallid herpesvirus 2, Marek-like viruses, turkey HV
    • C12N2710/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Abstract

The present invention provides a multiple DNA vaccine and/or a multivalent D NA vaccine for use in acquiring embryonic immunity in fowl eggs. The multiple D NA vaccine contains two or more DNA constructs, each containing a DNA molecule encoding an avian viral protein or a fragment thereof capable of inducing a protective immune response against the avian viral disease in fowl. The multivalent DNA vaccine contains one DNA construct which contains two or mor e DNA molecules, each representing an avian viral gene or a fragment thereof. The multivalent DNA vaccine is capable of expressing two or more viral antigens and inducing protective immune responses against the avian viral diseases in fowl.

Claims (30)

1. A multiple DNA vaccine for in ovo injection comprising:
two or more DNA constructs, each DNA construct expressing an antigenic protein of an avian virus causing avian viral disease in fowl; wherein said antigenic protein of said avian virus is capable of inducing a protective immune response against said avian viral disease in said fowl; and said multiple DNA vaccine is injected into egg of said fowl.
2. The multiple DNA vaccine according to claim 1, wherein said avian virus is one selected from the group consisting of Marek's disease virus (MDV), infectious vursal disease virus (IBDV), Newcastle disease virus (NDV), infectious bronchitis virus (IBV), infectious laryngotracheitis virus (ILTV), avian encephalomyelitis (AEV), avian leukosis virus (ALV), fowlpox virus (FPV), avian parainfluenza virus (APV), duck hepatitis virus (DHV), and hemorrhagic enteritis virus (HEV).
3. The multiple DNA vaccine according to claim 1, wherein said DNA construct comprises a DNA molecule encoding said antigenic protein of said avian virus and a vector.
4. The multiple DNA vaccine according to claim 1, wherein said vector is a plasmid or a viral carrier.
5. The multiple DNA vaccine according to claim 4, wherein said plasmid is one selected from the group consisting of pcDNA3, pVAX1, pSectag, pTracer, pDisplay, pUC
system plasmid, and pGEM system plasmid.
6. The multiple DNA vaccine according to claim 4, wherein said plasmid comprises a promoter which is selected from the group consisting of a CMV
promoter, SV40 promoter, RSV promoter, and .beta.-actin promoter.
7. The multiple DNA vaccine according to claim 4, wherein said viral carrier is one selected from the group consisting of a baculovirus, a herpes virus, and a pox virus.
8. The multiple DNA vaccine according to claim 3, wherein said DNA molecule is an entire of gB gene of Marek's Disease virus (MDV) having the DNA sequence of SEQ
ID NO:1 or a fragment thereof.
9. The multiple DNA vaccine according to claim 3, wherein said DNA molecule is an entire VP2 gene of infectious bursal disease virus (IBDV) having the DNA
sequence of SEQ ID NO:2 or a fragment thereof.
10. The multiple DNA vaccine according to claim 3, wherein said DNA
molecule is an entire HN gene of Newcastle disease virus (NDV) having the DNA
sequence of bases 6321 to 8319 in SEQ ID NO:3 or a fragment thereof.
11. The multiple DNA vaccine according to claim 3, wherein said DNA molecule is an entire S1 gene of infectious bronchitis virus (IBV) having the DNA
sequence of SEQ
ID NO:4 or a fragment thereof.
12. The multiple DNA vaccine according to claim 3, wherein said DNA molecule is an entire glycoprotein G gene of infectious laryngotracheitis virus (ILTV) having the DNA sequence of SEQ ID NO:S or a fragment thereof.
13. The multiple DNA vaccine according to claim 3, wherein said DNA molecule is an entire VP1, VP0, or VP3 gene of avian encephalomyelitis virus (AEV) or a fragment therof; wherein said VP1 gene has the DNA sequence of SEQ ID NO:6; said VP0 gene has the DNA sequence of SEQ ID NO:7; and said VP3 gene has the DNA sequence of SEQ
ID
NO:8.
14. The multiple DNA vaccine according to claim 3, wherein said DNA molecule is an entire paraglycoprotein G gene of avian parainfluenza virus (APV) having the DNA
sequence of SEQ ID NO:9 or a fragment thereof.
15. The multiple DNA vaccine according to claim 3, wherein said DNA molecule is an entire type A penton base gene of hemorrhagic enteritis virus (HEV) having the DNA
sequence of SEQ ID NO:10 or a fragment thereof.
16. The multiple DNA vaccine according to claim 3, wherein said DNA molecule is an entire envelope antigen gene of fowlpox virus (FPV) having the DNA
sequence of SEQ ID NO:11 or a fragment thereof.
17. The multiple DNA vaccine according to claim 1, wherein said multiple DNA
vaccine is injected into an amniotic fluid of said egg.
18. The multiple DNA vaccine according to claim 17, wherein said egg is fertilized for about 18 days.
19. The multiple DNA vaccine according to claim 1, wherein said DNA vaccine comprises two DNA constructs, each containing a DNA molecule capable of expressing a gene or a fragment thereof which is selected from the group consisting of Marelc's disease virus (MDV), infectious vursal disease virus (IBDV), Newcastle disease virus (NDV), infectious bronchitis virus (IBV), infectious laryngotracheitis virus (ILTV), avian encephalomyelitis (AEV), avian leukosis virus (ALV), fowlpox virus (FPV), avian parainfluenza virus (APV), duck hepatitis virus (DHV), and hemorrhagic enteritis virus (HEV).
20. The multiple DNA vaccine according to claim 1, wherein said DNA vaccine comprises three or more DNA constructs, each containing a DNA molecule capable of expressing a gene or a fragment thereof which is selected from the group consisting of Marek's disease virus (MDV), infectious vursal disease virus (IBDV), Newcastle disease virus (NDV), infectious bronchitis virus (IBV), infectious laryngotracheitis virus (ILTV), avian encephalomyelitis (AEV), avian leukosis virus (ALV), fowlpox virus (FPV), avian parainfluenza virus (APV), duck hepatitis virus (DHV), and hemorrhagic enteritis virus (HEV).
21. The multiple DNA vaccine according to claim 1, wherein said fowl is one selected from the group consisting of chicken, turkey, duck, and goose.
22. A method for vaccinating fowl egg comprising:
injecting into said fowl egg said multiple DNA vaccine according to claim 1.
23. A method for preparing said multiple DNA vaccine according to claim 1 comprising:
ligating a DNA molecule to a plasmid or virus carrier to form a DNA construct;
mixing two or more said DNA constructs to form said multiple DNA vaccine;
wherein said DNA molecule comprises a gene or a fragment thereof which is selected from the group consisting of Marek's disease virus (MDV), infectious vursal disease virus (IBDV), Newcastle disease virus (NDV), infectious bronchitis virus (IBV), infectious laryngotracheitis virus (ILTV), avian encephalomyelitis (AEV), avian leukosis virus (ALV), fowlpox virus (FPV), avian parainfluenza virus (APV), duck hepatitis virus (DHV), and hemorrhagic enteritis virus (HEV).
24. A multivalent DNA vaccine for in ovo injection comprising:
a DNA construct containing two or more DNA molecules, wherein each of said DNA molecules express an antigenic protein of an avian virus causing avian viral disease in fowl; wherein said antigenic protein of said avian virus is capable of inducing a protective immune response against said avian viral disease in said fowl; and said multivalent DNA vaccine is injected into egg of said fowl.
25. The multivalent DNA vaccine according to claim 22, wherein said DNA
molecules is a gene or a fragment thereof which is selected from the group consisting of Marek's disease virus (MDV), infectious vursal disease virus (IBDV), Newcastle disease virus (NDV), infectious bronchitis virus (IBV), infectious laryngotracheitis virus (ILTV), avian encephalomyelitis (AEV), avian leukosis virus (ALV), fowlpox virus (FPV), avian parainfluenza virus (APV), duck hepatitis virus (DHV), and hemorrhagic enteritis virus (HEV).
26. The multivalent DNA vaccine according to claim 24, wherein said DNA
construct further comprises a plasmid or a virus carrier.
27. The multivalent DNA vaccine according to claim 26, wherein said plasmid is one selected from the group consisting of pcDNA3, pVAX1, pSectag, pTracer, pDisplay, pUC system plasmid, and pGEM system plasmid.
28. The multiple DNA vaccine according to claim 26, wherein said plasmid comprises a promoter which is selected from the group consisting of a CMV
promoter, SV40 promoter, RSV promoter, and .beta.-actin promoter.
29. The multiple DNA vaccine according to claim 26, wherein said virus carrier is one selected from the group consisting of a baculovirus, a herpes virus, and a pox virus.
30. A method for vaccinating fowl egg comprising:
injecting into said fowl egg said multivalent DNA vaccine according to claim 24.
CA2478081A 2002-03-08 2003-03-06 Multiple and multivalent dna vaccines in ovo Expired - Fee Related CA2478081C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US36254702P 2002-03-08 2002-03-08
US60/362,547 2002-03-08
US10/377,718 2003-03-04
US10/377,718 US7029681B2 (en) 2002-03-08 2003-03-04 Multiple and multivalent DNA vaccines in ovo
PCT/US2003/006811 WO2003075843A2 (en) 2002-03-08 2003-03-06 Multiple and multivalent dna vaccines in ovo

Publications (2)

Publication Number Publication Date
CA2478081A1 true CA2478081A1 (en) 2003-09-18
CA2478081C CA2478081C (en) 2011-04-19

Family

ID=27807969

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2478081A Expired - Fee Related CA2478081C (en) 2002-03-08 2003-03-06 Multiple and multivalent dna vaccines in ovo

Country Status (10)

Country Link
US (1) US7029681B2 (en)
EP (1) EP1490105B1 (en)
JP (2) JP4999258B2 (en)
CN (2) CN101703770A (en)
AU (1) AU2003216531B2 (en)
BR (1) BRPI0308365B1 (en)
CA (1) CA2478081C (en)
IL (2) IL163859A0 (en)
MX (1) MXPA04008692A (en)
WO (1) WO2003075843A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7037506B2 (en) * 2002-03-08 2006-05-02 Schweltzer Chemical Corporation Ltd. Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
US8956628B2 (en) * 2007-12-13 2015-02-17 Zoetis Products Llc Bacteriophage preparations and method of use thereof
HUE041723T2 (en) 2011-10-21 2019-05-28 Intervet Int Bv Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
EP2768529A1 (en) * 2011-10-21 2014-08-27 Intervet International B.V. Recombinant nonpathogenic mdv vector providing multivalent immunity
EP2644702A1 (en) * 2012-03-30 2013-10-02 Ceva Sante Animale Multivalent recombinant avian herpes virus and vaccine for immunizing avian species
CN102895660B (en) * 2012-10-25 2014-04-23 中国兽医药品监察所 Bivalent inactivated vaccine for duck virus hepatitis
WO2015130492A1 (en) * 2014-02-25 2015-09-03 The United States Of America, As Represented By The Secretary Of Agriculture Novel immunogenic composition
CN110295149B (en) * 2019-06-24 2022-06-24 四川农业大学 Mutant strain 3 type duck hepatitis A virus CH-P60-117C strain and construction method thereof

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US182241A (en) * 1876-09-12 Improvement in animal-traps
US3575A (en) * 1844-05-06 Improvement
US4458630A (en) 1982-06-22 1984-07-10 The United States Of America As Represented By The Secretary Of Agriculture Disease control in avian species by embryonal vaccination
WO1990002802A2 (en) * 1988-09-13 1990-03-22 Institute For Animal Health Limited Viral nucleotide sequences
US5397568A (en) 1989-10-02 1995-03-14 Whitfill; Craig E. Method of treating infectious bursal disease virus infections
ATE200735T1 (en) 1989-10-02 2001-05-15 Univ Arkansas VACCINE CONJUGATE
US5056464A (en) 1990-01-18 1991-10-15 Embrex, Inc. Automated injection system for avian embryos with advanced fluid delivery system
US5595912A (en) 1990-05-04 1997-01-21 University Of Maryland College Park Specific DNA and RNA sequences associated with US IBDV variants, vector carrying DNA sequences, host carrying cloned vector, deduced amino acid sequences, vaccine and method of vaccination
ZA924203B (en) 1991-06-18 1993-03-31 Akzo Nv Coccidiosis poultry vaccine
US5643578A (en) 1992-03-23 1997-07-01 University Of Massachusetts Medical Center Immunization by inoculation of DNA transcription unit
JPH06141853A (en) * 1992-10-30 1994-05-24 Chemo Sero Therapeut Res Inst Recombinant avian infectious laryngotrachitis inducing virus and its producing
CA2156423A1 (en) * 1993-02-26 1994-09-01 Mark D. Cochran Recombinant fowlpox viruses and uses thereof
EP0745127A4 (en) * 1994-01-11 1999-10-20 Cornell Res Foundation Inc Control of marek's disease by the inhibition of latency and tumor cell development
US5817320A (en) 1994-06-20 1998-10-06 The United States Of America As Represented By The Secretary Of The Agriculture In ovo immunization of avian embryos with oil-emulsion vaccines
WO1995035121A1 (en) 1994-06-20 1995-12-28 The United States Of America, Represented By The Secretary, Department Of Agriculture In ovo immunization of avian embryos with oil-emulsion vaccines
JPH08116976A (en) * 1994-10-20 1996-05-14 Chemo Sero Therapeut Res Inst Nucleic acid preparation for immunization and immunizing method using the acid
AU710080B2 (en) 1995-07-07 1999-09-16 Nippon Zeon Co., Ltd. Marek's disease virus genes and their use in vaccines for protection against Marek's disease
FR2751225B1 (en) * 1996-07-19 1998-11-27 Rhone Merieux AVIAN POLYNUCLEOTIDE VACCINE FORMULA
US5699751A (en) 1996-10-02 1997-12-23 Embrex, Inc. Method and apparatus for in ovo injection
US6048535A (en) * 1997-06-12 2000-04-11 Regents Of The University Of Minnesota Multivalent in ovo avian vaccine
JP4091152B2 (en) * 1997-09-19 2008-05-28 財団法人化学及血清療法研究所 Nucleic acid preparations containing colloidal gold
UY25347A1 (en) 1998-01-12 1999-05-14 Embrex Inc MULTIPLE INJECTION PROCEDURE FOR THE TREATMENT OF AVIAN EMBRYOS IN OVO, AND AUTOMATED DEVICE FOR INJECTION IN OVO.
US6286455B1 (en) 1998-01-12 2001-09-11 Embrex, Inc. Automated in ovo injection apparatus

Also Published As

Publication number Publication date
AU2003216531B2 (en) 2006-11-30
JP2005519943A (en) 2005-07-07
US7029681B2 (en) 2006-04-18
EP1490105A2 (en) 2004-12-29
IL163859A (en) 2010-05-17
US20030175291A1 (en) 2003-09-18
CN101703770A (en) 2010-05-12
CA2478081C (en) 2011-04-19
IL163859A0 (en) 2005-12-18
JP2009203242A (en) 2009-09-10
MXPA04008692A (en) 2005-02-24
BRPI0308365B1 (en) 2016-12-27
CN1646157B (en) 2011-03-02
WO2003075843A3 (en) 2004-07-22
WO2003075843A2 (en) 2003-09-18
EP1490105A4 (en) 2006-04-19
CN1646157A (en) 2005-07-27
EP1490105B1 (en) 2013-10-02
AU2003216531A1 (en) 2003-09-22
JP4999258B2 (en) 2012-08-15
BR0308365A (en) 2005-09-06

Similar Documents

Publication Publication Date Title
RU2019136150A (en) VACCINES AGAINST RECOMBINANT HERPESVIRUS GALLID 3, CODING HETEROLOGICAL ANTIGENS OF THE AVIAN PATHOGEN
RU2766003C2 (en) Multivalent recombinant avian herpes viruses and vaccines for immunisation of birds
US6464984B2 (en) Avian polynucleotide vaccine formula
Fodor et al. Induction of protective immunity in chickens immunised with plasmid DNA encoding infectious bursal disease virus antigens
AR008620A1 (en) RECOMBINANT LIVING VACCINE, DNA FRAGMENT AND ILTV VIRUSES THAT MAKE IT
RU2016112951A (en) Recombinant viruses Marek's disease and their application
Loke et al. Improved protection from velogenic Newcastle disease virus challenge following multiple immunizations with plasmid DNA encoding for F and HN genes
Sun et al. Protection of chickens from Newcastle disease and infectious laryngotracheitis with a recombinant fowlpox virus co-expressing the F, HN genes of Newcastle disease virus and gB gene of infectious laryngotracheitis virus
JP2009203242A5 (en)
CA2283093A1 (en) Recombinant chimeric viruses and uses thereof
CA2478081A1 (en) Multiple and multivalent dna vaccines in ovo
Fingerut et al. A subunit vaccine against the adenovirus egg-drop syndrome using part of its fiber protein
JPH06509235A (en) Infectious Bursal Disease Virus Recombinant Poxvirus Vaccine
JP2018519826A (en) Duck enteritis virus and use thereof
AU729518B2 (en) Recombinant fowlpox viruses and uses thereof
Cavanagh Recent advances in avian virology
TWI224139B (en) Processes for preparation of Marek's disease virus using continuous avian cell lines
Boyle et al. Influence of dose and route of inoculation on responses of chickens to recombinant fowlpox virus vaccines
Hirai et al. Polyvalent recombinant Marek’s disease virus vaccine against poultry diseases
US5658572A (en) Infectious bursal disease virus recombinant poxvirus vaccine
Tomley Recombinant vaccines for poultry
RU2021120675A (en) RECOMBINANT AVIAN HERPES VIRUSES CONTAINING SEVERAL FOREIGN GENES
US7037506B2 (en) Vaccine accelerator factor (VAF) for improvement of vaccinations in poultry
RU2021120823A (en) RECOMBINANT VIRUSES AND THEIR APPLICATIONS
MXPA98004669A (en) Preparation of marek's disease viruses using mamif continuous cell lines

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20220908

MKLA Lapsed

Effective date: 20210308